Decision: Favourable
Study Title:
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VR
NREC Code:
22-NREC-CT-102
Decision:
Favourable
Meeting Date:
08/06/2022
Study Type:
CT application
Principal Investigator:
Professor Christopher Bacon
PI Institution:
St James' Hospital
Sponsor:
Janssen-Cilag International NV